中文

Agios falls 18% as FDA delays sickle cell decision over safety review

By · AI-assisted, human-reviewed and edited · · Updated · 10 sources · Fact-checked · 3 min read

Why is Agios Pharmaceuticals stock down today?

Agios shares fell 17.9% on Friday after the company said the FDA had extended its review of mitapivat for sickle cell disease by three months, to Feb 1, 2027. The FDA had asked whether the drug needs a formal safety program because of liver-injury risk, and it classed Agios's answer as a major amendment and extended the review by three months. Agios says the drug's benefit-risk profile is unchanged and that it is ready to launch.

What it means

What changed
The FDA's sickle cell decision moved three months later, to Feb 1, 2027, while it weighs whether mitapivat needs a REMS safety program.
What hasn't changed
The application is still under review, and mitapivat is still sold in the US for PK deficiency and thalassemia.
Next · Nov 5, 2026 (confirmed)
Agios reports third-quarter results and hosts a conference call at 8 a.m. ET.
Move
▼ 17.9%
Price
$37.23 → $30.55
Value lost
~$0.40B
New FDA goal date
Feb 1, 2027
Mitapivat sales, Q2
$44.7M
Cash, June 30
$964.8M

Prices: official close, Nasdaq (Stock Analysis daily history), Oct 30, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean

Closing prices: $30.55 on Oct 30, 2026, versus $37.23 on Oct 29, according to Stock Analysis.

Snapshot at the Oct 30, 2026 close

Enterprise value
$856M
Price/sales
18.5×
P/E
n/m
Revenue growth
+141%
FCF margin
−371%
Net cash
$965M

Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Jul 30, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $30.55 (official close, Nasdaq (Stock Analysis daily history)). n/m = not meaningful (e.g. negative earnings).

What happened

Agios fell after it said the FDA needs three more months to decide on mitapivat for sickle cell disease, the largest patient group it has pursued for the drug, while the agency weighs whether it should come with a formal safety program.

  • Agios said before the market opened on Oct 30 that the FDA had moved its PDUFA date, the target date for its decision, from Nov 1, 2026 to Feb 1, 2027.
  • On Oct 9, the FDA asked for information to evaluate whether mitapivat needs a REMS (Risk Evaluation and Mitigation Strategy) in sickle cell disease. A REMS is a safety program that can require blood tests, patient enrollment and certification of prescribers and pharmacies.
  • Agios replied on Oct 19 with about nine months of new safety data from the extension periods of its RISE UP trials. Agios said the FDA classified its response as a major amendment on Oct 28 and extended the review by three months.
  • Agios said there are still no cases of hepatocellular (liver-cell) injury in sickle cell patients like those seen in its thalassemia trials, and that the drug’s benefit-risk profile is unchanged. Chief executive Brian Goff said the company is “launch-ready.” Agios will continue labeling talks with the FDA, “including elements of a potential REMS.”
  • Agios closed at $30.55, down 17.9% from Thursday’s $37.23 close, according to Stock Analysis. Using the 59.7 million shares Agios reported outstanding on July 24, that is about $0.40 billion of market value lost (our calculation: $6.68 × 59.7 million). The stock had been worth about $2.2 billion before the news.
  • The broader market also fell. The S&P 500 closed down 1.8% and the Nasdaq Composite fell 2.9%, according to AP.

Why the market reacted this way

Goff said sickle cell disease affects about 100,000 people in the US and is the largest patient population Agios has pursued for mitapivat. The drug is already sold in the US for two rarer blood disorders. The three-month extension could delay sickle cell sales if mitapivat is approved; approval and launch timing remain uncertain. A REMS, if required, would add steps before patients can start treatment.

Agios has been here before. In thalassemia, the FDA also extended its review by three months in September 2025, after Agios submitted a proposed REMS for liver-injury risk. The FDA then missed the extended date and approved the drug on Dec 23, 2025. It is sold for thalassemia as AQVESME, only through a REMS that requires liver tests before the first dose and every four weeks for the first 24 weeks, plus patient enrollment and certification of prescribers and pharmacies. The US launch began in late January 2026. By June 30, REMS-certified doctors had written 442 prescriptions. Mitapivat’s total sales were $44.7 million in the second quarter.

The sickle cell evidence

Agios reported that mitapivat improved hemoglobin, the oxygen-carrying protein in red blood cells, but did not meet the trial’s other main goal of reducing pain crises. In the 207-patient RISE UP Phase 3 trial, 40.6% of patients taking mitapivat met the hemoglobin-response goal, compared with 2.9% taking placebo. That goal required an increase of at least 1 gram per deciliter in average hemoglobin during weeks 24–52. Agios reported annual pain-crisis rates of 2.62 per patient on mitapivat and 3.05 on placebo; the difference did not meet the trial’s statistical threshold for showing a treatment effect.

That is why Agios is seeking accelerated approval, an FDA route that allows approval on an early measure of benefit if the company later confirms it in another trial. Its ongoing REIGNITE Phase 3 trial tests whether mitapivat reduces blood-transfusion needs in sickle cell disease.

Does this change Agios’s future?

Our read: the decision target moved back three months, and approval, the final safety requirements and launch timing remain uncertain. Agios had $964.8 million of cash and marketable securities on June 30. It lost $100.7 million in the second quarter, which included a $25 million licensing payment, and says its cash and product revenue give it the “financial independence” to prepare a sickle cell launch.

The other view

Agios says the extension does not change mitapivat's benefit-risk profile in sickle cell disease, that it has seen no sickle cell cases of liver-cell injury like those in thalassemia, and that it is launch-ready.

Source: Agios release, Oct 30, 2026 (via Stock Titan)

What to watch next

Before Feb 1, 2027
Agios's labeling talks with the FDA, including whether the sickle cell label comes with a REMS safety program like the one for thalassemia.
Feb 1, 2027
The new FDA goal date for mitapivat in sickle cell disease. In thalassemia, the FDA missed its extended date and approved the drug about two weeks later.
Nov 5, 2026
Agios will report third-quarter results and host a conference call at 8 a.m. ET.
Ongoing
Agios's ongoing REIGNITE Phase 3 trial tests whether mitapivat reduces blood-transfusion needs in sickle cell disease. It is the confirmatory trial for the accelerated-approval application.

Quick questions

Did the FDA reject mitapivat for sickle cell disease?

No. The FDA moved its target decision date from Nov 1, 2026 to Feb 1, 2027 after classing Agios's response to a safety question as a major amendment. The application is still under review.

What is the FDA asking about?

On Oct 9 the FDA asked for information to judge whether mitapivat needs a Risk Evaluation and Mitigation Strategy (REMS) in sickle cell disease. In thalassemia, the drug is sold only under a REMS that requires regular liver tests because of a risk of liver injury, plus patient enrollment and certification of prescribers and pharmacies.

Has this happened to Agios before?

Yes. In September 2025 the FDA extended its review of mitapivat in thalassemia by three months after Agios submitted a proposed REMS. The FDA missed the extended date and approved the drug on Dec 23, 2025, with a REMS.

About Agios Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.